Trierucin

CAS : 2752-99-0

Ref. 3D-CAA75299

Informations sur le produit

• Nom: Trierucin
• Synonymes: 13-Docosenoic acid, 1,2,3-propanetriyl ester, (Z,Z,Z)-, 13-Docosenoin, tri-, (Z,Z,Z)-, 13-Docosenoic acid, 1,2,3-propanetriyl ester, (13Z,13′Z,13′′Z)-, Erucin, tri-, 13-Docosenoic acid, 1,1′,1′′-(1,2,3-propanetriyl) ester, (13Z,13′Z,13′′Z)-

Description

Trierucin is a pharmaceutical preparation that contains fatty acids, which are synthesized by the body. Trierucin has been shown to increase cardiac enzyme activity in rats and to have cationic surfactant properties in vitro. Trierucin has also been used as a treatment for adrenoleukodystrophy (ALD) and chronic oral fatty acid supplements. ALD is an X-linked genetic disorder that affects fatty acid metabolism and leads to progressive damage of nerve cells in the brain and spinal cord. The symptoms of this disease include skin lesions, mental deterioration, seizures, blindness, and coma. Treatment with trierucin has been shown to reduce neurological impairment in mice with ALD. Trierucin may also be used to treat tumors because it inhibits tumor cell proliferation by altering cellular organelle function.br>
Trierucin is a pharmaceutical preparation that contains fatty acids, which are synthesized by the body. Trierucin has been shown to increase

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 1,053.75 g/mol
• Formule: C₆₉H₁₂₈O₆
• Degré de pureté: Min. 95%